The U.S. anti-biofilm wound dressing market size was valued at USD 314.2 million in 2024 and is projected to reach USD 546.3 million by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The market's growth can be attributed to the growing prevalence of chronic and acute wounds owing to the increase in chronic diseases, including diabetes, cancer, cardiovascular diseases, and other autoimmune diseases.
According to the U.S. Centers for Disease Control and Prevention, as of 2021, over 38 million people, over 11% of the overall U.S. population, had diabetes. The country's increasing number of road accidents significantly contributes to the market's growth. According to the U.S. Department of Transportation’s National Highway Traffic Safety Administration, over 39,000 people died in road accidents in 2024. The growing number of road accidents increases the demand for wound care products with anti-biofilm properties, as these accidents can lead to severe burns and traumatic injuries. The increasing government and private investments in advanced wound care technologies to improve patient outcomes and lower healthcare costs further contribute to the market's growth.
Regulatory frameworks ensure safety and efficacy and promote the adoption of advanced antimicrobial dressings, while end-use concentration highlights the significance of key healthcare segments such as hospitals, specialty clinics, and outpatient clinics in driving demand.
Innovation remains crucial as companies invest heavily in R&D to develop dressings with enhanced anti-biofilm capabilities. In April 2025, Convatec announced its plans for the initial market launch of ConvaNiox, a new technology powered by a potent antimicrobial and antibiofilm agent, nitric oxide, which is supported by strong clinical evidence. ConvaNiox will be initially used for the management of diabetic foot ulcers (DFUs), which has been demonstrated to reduce the wound area three times faster and increase DFU healing by 60% in comparison to the standard of care.
The rising incidence of diabetes, alongside an aging demographic, further increases the demand, urging manufacturers to increase production and broaden their product ranges to cater to the sector's specific requirements. For instance, numerous companies have enhanced their manufacturing capabilities within the U. S. and fortified their distribution networks to serve healthcare providers better.
This product will be delivered within 2 business days.
According to the U.S. Centers for Disease Control and Prevention, as of 2021, over 38 million people, over 11% of the overall U.S. population, had diabetes. The country's increasing number of road accidents significantly contributes to the market's growth. According to the U.S. Department of Transportation’s National Highway Traffic Safety Administration, over 39,000 people died in road accidents in 2024. The growing number of road accidents increases the demand for wound care products with anti-biofilm properties, as these accidents can lead to severe burns and traumatic injuries. The increasing government and private investments in advanced wound care technologies to improve patient outcomes and lower healthcare costs further contribute to the market's growth.
Regulatory frameworks ensure safety and efficacy and promote the adoption of advanced antimicrobial dressings, while end-use concentration highlights the significance of key healthcare segments such as hospitals, specialty clinics, and outpatient clinics in driving demand.
Innovation remains crucial as companies invest heavily in R&D to develop dressings with enhanced anti-biofilm capabilities. In April 2025, Convatec announced its plans for the initial market launch of ConvaNiox, a new technology powered by a potent antimicrobial and antibiofilm agent, nitric oxide, which is supported by strong clinical evidence. ConvaNiox will be initially used for the management of diabetic foot ulcers (DFUs), which has been demonstrated to reduce the wound area three times faster and increase DFU healing by 60% in comparison to the standard of care.
The rising incidence of diabetes, alongside an aging demographic, further increases the demand, urging manufacturers to increase production and broaden their product ranges to cater to the sector's specific requirements. For instance, numerous companies have enhanced their manufacturing capabilities within the U. S. and fortified their distribution networks to serve healthcare providers better.
U.S. Anti-biofilm Wound Dressing Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. anti-biofilm wound dressing market report based on mode of mechanism, application, and end-use:Mode of Mechanism (Revenue, USD Million, 2018 - 2030)
- Physical
- Manual Debridement
- Pulse Electrical Field
- Ultrasound Debridement
- Chemical
- Ionic Silver
- Iodine
- EDTA
- Others
- Biological
- Dispersin B
- Lactoferrin
- Bacteriophage
- Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
- Chronic Wounds
- Diabetic Foot Ulcers
- Pressure Ulcers
- Venous Leg Ulcers
- Others
- Acute Wounds
- Surgical & Traumatic Wounds
- Burn Wounds
End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Anti-biofilm Wound Dressing Market Variables, Trends & Scope
Chapter 4. U.S. Anti-biofilm Wound Dressing Market: Mode of Mechanism Estimates & Trend Analysis
Chapter 5. U.S. Anti-biofilm Wound Dressing Market: Application Estimates & Trend Analysis
Chapter 6. U.S. Anti-biofilm Wound Dressing Market: End-Use Estimates & Trend Analysis
Chapter 7. U.S. Anti-biofilm Wound Dressing Market - Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- ConvaTec Inc.
- Smith & Nephew PLC
- Imbed Biosciences
- Next Science
- B. Braun Melsungen AG
- 3M
- Molnlycke Health Care AB
- Coloplast
- Lohmann & Rauscher
